RIGL
Rigel Pharmaceuticals Inc
NASDAQ: RIGL · HEALTHCARE · BIOTECHNOLOGY
$29.22
-4.38% today
Updated 2026-04-29
Market cap
$564.75M
P/E ratio
1.57
P/S ratio
1.92x
EPS (TTM)
$19.48
Dividend yield
—
52W range
$17 – $52
Volume
0.4M
Rigel Pharmaceuticals Inc (RIGL) Financial statements
SEC filings — annual and quarterly data.
Profit margin
124.70%
Operating margin
33.20%
ROE
185.90%
ROA
23.20%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $33.47M | $-37.64M | 100.00% | -128.60% | -112.44% |
| 2007 | $12.60M | $-74.27M | 100.00% | -631.17% | -589.46% |
| 2008 | — | $-132.35M | — | — | — |
| 2009 | $750000.00 | $-111.55M | 100.00% | -14,938.27% | -14,872.93% |
| 2010 | $125.00M | $37.89M | 100.00% | 28.25% | 30.31% |
| 2011 | $4.75M | $-85.97M | 100.00% | -1,818.27% | -1,809.96% |
| 2012 | $2.25M | $-98.84M | 100.00% | -4,416.76% | -4,392.89% |
| 2013 | $7.15M | $-89.03M | -953.54% | -1,251.31% | -1,245.13% |
| 2014 | $8.25M | $-90.91M | -720.56% | -1,106.05% | -1,101.92% |
| 2015 | $28.89M | $-51.46M | -117.43% | -179.07% | -178.11% |
| 2016 | $20.38M | $-69.22M | -211.27% | -342.15% | -339.58% |
| 2017 | $4.48M | $-77.99M | -931.87% | -1,775.56% | -1,739.34% |
| 2018 | $44.51M | $-70.48M | 99.36% | -163.30% | -158.35% |
| 2019 | $59.29M | $-66.55M | 98.47% | -116.53% | -112.24% |
| 2020 | $108.62M | $-29.74M | 99.18% | -26.67% | -27.38% |
| 2021 | $149.24M | $-17.91M | 99.27% | -8.37% | -12.00% |
| 2022 | $120.24M | $-58.57M | 98.55% | -46.20% | -48.71% |
| 2023 | $116.88M | $-25.09M | 93.92% | -17.53% | -21.47% |
| 2024 | $179.28M | $17.48M | 89.60% | 13.49% | 9.75% |
| 2025 | $294.28M | $367.02M | 93.33% | 42.63% | 124.72% |